RE: AGM12 Sep 2024 20:16
Let's examine his pre-Synairgen role Doc83, for context.
Pre-Synairgen, he also "walked away" from a rewarding job when he was at an earlier peak peak, working on a specific drug ( what would become the blockbuster therapeutic antibody, Humira), when he was paid a very decent salary and only had to meet his ultimate bosses once each year. And yet, he decided then too to throw the towel in, just as said drug and company Cambridge Antibody Technology (CAT), the the biggest success story in UK biotech, became part of you know who (AstraZeneca} in 2006, in a £702M acquisition.
So you see we can't just assume that he isn't walking away to his next challenge, whatever that may be (Fulltime research in Academia? NFP? Travel? Family? ), because that's exactly what he did before. And with a new CMO now fully onboarded into the company, you could assume there really is no longer the scope to the job that there once was. I's imagine t becomes less enticing to stay in such circumstances...
Not saying any of this is happening, but if it's balance you seek, you should be examining more than one outcome based on the facts as we know them.